ESH 2017 | Therapeutics targeting splicing in hematological malignancies
Omar Abdel-Wahab
Currently, the majority of therapeutics that target splicing mutations in hematological malignancies are in the early or pre-clinical phases. In this video, Omar Abdel-Wahab, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses one such exciting trial, NCT02841540. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).
Similar topics
Related videos

Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery

Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill

An exciting era for CAR T-cell therapy
Mohamad Mohty

Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno

JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
More from Omar Abdel-Wahab